Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
BMC Med. 2023 Apr 17;21(1):147. doi: 10.1186/s12916-023-02838-2.
Tyrosine kinase inhibitors (TKIs) are anti-cancer therapeutics often prescribed for long-term treatment. Many of these treatments cause cardiotoxicity with limited cure. We aim to clarify molecular mechanisms of TKI-induced cardiotoxicity so as to find potential targets for treating the adverse cardiac complications.
Eight TKIs with different levels of cardiotoxicity reported are selected. Phenotypic and transcriptomic responses of human cardiomyocytes to TKIs at varying doses and times are profiled and analyzed. Stress responses and signaling pathways that modulate cardiotoxicity induced by three TKIs are validated in cardiomyocytes and rat hearts.
Toxicity rank of the eight TKIs determined by measuring their effects on cell viability, contractility, and respiration is largely consistent with that derived from database or literature, indicating that human cardiomyocytes are a good cellular model for studying cardiotoxicity. When transcriptomes are measured for selected TKI treatments with different levels of toxicity in human cardiomyocytes, the data are classified into 7 clusters with mainly single-drug clusters. Drug-specific effects on the transcriptome dominate over dose-, time- or toxicity-dependent effects. Two clusters with three TKIs (afatinib, ponatinib, and sorafenib) have the top enriched pathway as the endoplasmic reticulum stress (ERS). All three TKIs induce ERS in rat primary cardiomyocytes and ponatinib activates the IRE1α-XBP1s axis downstream of ERS in the hearts of rats underwent a 7-day course of drug treatment. To look for potential triggers of ERS, we find that the three TKIs induce transient reactive oxygen species followed by lipid peroxidation. Inhibiting either PERK or IRE1α downstream of ERS blocks TKI-induced cardiac damages, represented by the induction of cardiac fetal and pro-inflammatory genes without causing more cell death.
Our data contain rich information about phenotypic and transcriptional responses of human cardiomyocytes to eight TKIs, uncovering potential molecular mechanisms in modulating cardiotoxicity. ER stress is activated by multiple TKIs and leads to cardiotoxicity through promoting expression of pro-inflammatory factors and cardiac fetal genes. ER stress-induced inflammation is a promising therapeutic target to mitigate ponatinib- and sorafenib-induced cardiotoxicity.
酪氨酸激酶抑制剂 (TKI) 是常用于长期治疗的抗癌治疗药物。这些治疗方法中有许多会导致心脏毒性,且治疗效果有限。我们旨在阐明 TKI 诱导的心脏毒性的分子机制,以便找到治疗心脏不良并发症的潜在靶点。
选择了 8 种具有不同程度心脏毒性报道的 TKI。在不同剂量和时间下,对 TKI 对人心肌细胞的表型和转录组反应进行了分析。在心肌细胞和大鼠心脏中验证了调节三种 TKI 诱导的心脏毒性的应激反应和信号通路。
通过测量 8 种 TKI 对细胞活力、收缩力和呼吸的影响来确定的毒性等级,在很大程度上与从数据库或文献中得出的等级一致,这表明人心肌细胞是研究心脏毒性的良好细胞模型。当对人心肌细胞中具有不同毒性水平的选定 TKI 治疗进行转录组测量时,数据分为 7 个主要为单药聚类的聚类。药物对转录组的特异性作用超过了剂量、时间或毒性依赖性作用。有两个聚类(阿法替尼、帕纳替尼和索拉非尼)的通路主要富集于内质网应激 (ERS)。三种 TKI 均诱导大鼠原代心肌细胞中的 ERS,ponatinib 在经历 7 天药物治疗的大鼠心脏中激活 ERS 下游的 IRE1α-XBP1s 轴。为了寻找 ERS 的潜在触发因素,我们发现三种 TKI 诱导短暂的活性氧,随后发生脂质过氧化。在 ERS 下游抑制 PERK 或 IRE1α 可阻断 TKI 诱导的心脏损伤,表现为诱导心脏胎儿和促炎基因的表达,而不会导致更多的细胞死亡。
我们的数据包含了丰富的信息,说明了人心肌细胞对 8 种 TKI 的表型和转录组反应,揭示了调节心脏毒性的潜在分子机制。内质网应激被多种 TKI 激活,并通过促进促炎因子和心脏胎儿基因的表达导致心脏毒性。内质网应激诱导的炎症是减轻 ponatinib 和 sorafenib 诱导的心脏毒性的一个有前途的治疗靶点。